---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127027"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:26:30.930664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025

## Summary
- Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.
- Cash and investments $340.1M, expected to fund operations into H2 2026.
- R&D expenses rose to $30.1M from $27.9M, driven by GBS, GA, and ANX1502 programs.
- ANX005 GBS: topline RWE comparability data expected year-end 2024; BLA submission targeted H1 2025.
- Strengthened commercial and medical affairs leadership with three senior appointments.

## SEC filing metadata
- accession: 0000950170-24-127027
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/0000950170-24-127027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/annx-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127027
- JSON: https://secwatch.observer/filing/0000950170-24-127027.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.